COVID-19 pneumonia and clinical follow-up: results of a prospective cohort | European Respiratory Society

Tables

Age(yrs)	59(46-72)
Male(%)	37(51.4)
Chronic Lung Disease, total(%) Former/Actual Smoker COPD Asthma	36(50) 24(33.3) 5(6.9) 2(2.8)
Hypertension(%)	26(36.1)
Diabetes(%)	13(18.1)
Immunosuppresion(%)	11(15.3)
Fever Cough Dyspnea	56(77.8) 42(58.3) 40(55.6)
O2 required(%)	48(66.7)
COVID treatment(%) Convalescent plasma + Steroids Steroids	51(70.8) 37(51.4) 14(19.4)

	Non-Extent pneumonia	Extent pneumonia	p value
Immunosuppression(%)	0(0)	11(20.4)	0.037
Fever(%)	9(12.5)	47(65.3)	0.001
Dyspnea(%)	6(8.3)	34(47.2)	0.028
O2 required(%)	7(9.7)	41(56.9)	0.004
Symptom persistence	2(2.8)	6(8.33)	0.001

Vol 58 Issue suppl 65 Table of Contents

More in this TOC Section

Hypovitaminosis D and severity of COVID19 respiratory infection in a respiratory intensive care unit (RICU) in Apulia southern Italian region
Prognostic usefulness of severity scales for the initial assessment of elderly people with a diagnosis of pneumonia due to COVID-19. Design of a multivariate predictive model of mortality
Usefulness of CURB-65, PSI and MuLBSTA in predicting COVID-19 mortality

Show more Respiratory infections and bronchiectasis

Related Articles